Beckman Coulter Life Sciences has acquired ValitaCell, an analytical technologies and product provider for the biopharmaceutical industry. Under the terms of the deal, US-headquartered laboratory and automation firm Beckman Coulter Life Sciences — a subsidiary of Danaher Corporation, which owns bioprocess vendors Cytiva and Pall — has bought Dublin-headquartered ValitaCell for an undisclosed fee. ValitaCell has an aim of decreasing the cost of therapeutics and the time it takes to get to market. And according to ValitaCell, its ValitaTiter product…

National Resilience and MD Cancer Center joint venture CTMC will be granted precommercial access to Ori Biotech’s paperless technology platform. The Cell Therapy Manufacturing Center (CTMC) will be part of Ori’s LightSpeed Early Access Program (LEAP) as it looks to accelerate process development, commercialization, and clinical implementation of cell therapies. Both parties have outlined numerous key objectives for the collaboration. The CTMC will assess its current CAR-T processes already ongoing in its development space onto Ori’s platform to highlight technical…

The partnership will see Selexis and NexImmune collaborate to develop cell lines targeting autoimmune diseases and rare cancers. Under the terms of the deal, of which financial details have not been disclosed, NexImmune will use Selexis’ SUREtechnology to develop cell lines to treat rare cancers, autoimmune diseases, and advance two human leukocyte antigens (HLAs), which can be used to increase treatments to more individuals. “There is a growing global demand for biologics and therapeutics. Specifically, a growing industry is developing…

Through the reverse merger of Medsenic, Bone Therapeutics will broaden and derisk its portfolio while increasing funding opportunities, the firm says. France-based firm Medsenic specializes in the advancement of optimized formulations of arsenic salts targeting inflammatory conditions and other indications. Under the terms of the deal, Bone Therapeutics will acquire 51 percent of Medsenic shares, valued at $40 million. Together, Bone Therapeutics and Medsenic will create a new biopharma company under the name BioSenic. According to both parties, the integration…

The partnership will see CDMO Lonza integrate Touchlight’s doggybone DNA tech into its messenger RNA (mRNA) manufacturing offering. Swiss contract development and manufacturing organization (CDMO) Lonza has been at the forefront of mRNA production, in part due to major contracts to supply the drug substance for hundreds of millions of doses of Moderna’s COVID-19 vaccine, Spikevax. It’s oligonucleotide and RNA production capabilities have also been bolstered through various investments across its global network, including an expansion at its Visp, Switzerland…

Biotech investor Glenn Haifer and private equity firm Ampersand Capital Partners have acquired microbial CDMO LuinaBio and renamed it AcuraBio. LuinaBio has been a microbial contract development and manufacturing organization (CDMO) for over 20 years but will now be rebranded as AcuraBio following the acquisition. No financials have been disclosed but the new owners, Haifer and Ampersand, plan to increase the contract development and manufacturing organization’s (CDMO) production facility capacity, located near Brisbane, Australia. “We are very excited to be…

ChargePoint Technology has acquired PuroVaso, a development and production firm of single-use containers, equipment, and accessories for the biopharma industry. The deal, of which financial details are undisclosed, sees liquid and powder transfer firm ChargePoint acquire PuroVaso to complement “the existing product range, giving pharmaceutical manufacturers a broader choice of world-class powder and liquid transfer, storage, and handling products that solve customers’ application-specific problems with enhanced productivity,” a spokesperson for the firm told us. According to ChargePoint, the decision to…